Quadrant Capital Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Quadrant Capital Group’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15	Closed	-$362	–	2818
2023 Q1	$362	Buy	+15	New	+$188	﹤0.01%	2632
2022 Q2	–	Sell	-147	Closed	-$1K	–	2827
2022 Q1	$1K	Hold	147	–	–	﹤0.01%	2452
2021 Q4	$1K	Hold	147	–	–	﹤0.01%	2458
2021 Q3	$1K	Buy	147 +125	+568%	+$803	﹤0.01%	2446
2021 Q2	$0	Buy	+22	New	+$178	﹤0.01%	2623

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Quadrant Capital Group's PRVB Position: Q2 2023 in Review

Quadrant Capital Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 15 shares — an estimated $362 sold.

Quadrant Capital Group first reported a position in PRVB in Q2 2021 and held it in 5 quarters. The position peaked at $1K in Q1 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Quadrant Capital Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Quadrant Capital Group sold 15 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $362.
Quadrant Capital Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Quadrant Capital Group's Provention Bio, Inc. Common Stock position peaked at $1K in Q1 2022.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.